Financhill
Back

Akebia Therapeutics Quote, Financials, Valuation and Earnings

Write This Down: Tuesday at 2 p.m. ET!

Don't Miss Our LIVE Trade
Buy
66

AKBA
Akebia Therapeutics

Last Price:
1.86
Seasonality Move:
32.87%

7 Day Trial

ALL ACCESS PASS

$ 7

The Mysterious VC Firm Behind Nvidia's Secret Weapon

Details Here!

Akebia Therapeutics Price Quote

$1.86

Akebia Therapeutics Key Stats

Buy
66
Akebia Therapeutics (AKBA) is a Buy

Day range:
$1.78 - $1.86
52-week range:
$0.80 - $2.48
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
2.11
P/B ratio:
0%

Volume:
2.5M
Avg. volume:
1.7M
1-year change:
96.85%
Market cap:
$391.1M
Revenue:
$194.6M
EPS:
$-0.21

How Much Does Akebia Therapeutics Make?

Is Akebia Therapeutics Growing As A Company?

  • What Is Akebia Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.23%
  • What Is Akebia Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Akebia Therapeutics Stock Price Performance

What Is Akebia Therapeutics 52-Week High & Low?

Akebia Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Akebia Therapeutics?

Is Akebia Therapeutics Cash Flow Positive?

  • What Is AKBA Cash Flow From Operations?
    Cash flow from operations (TTM) is -$39M
  • What Is Akebia Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $24.9M
  • What Is Akebia Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$29K

Akebia Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    AKBA return on invested capital is -671.06%
  • What Is Akebia Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -17.19%
  • What Is AKBA Return On Equity?
    ROE is a measure of profitability and is 0%

Akebia Therapeutics Earnings Date & Stock Price

Akebia Therapeutics Competitors

  • Who Are Akebia Therapeutics's Competitors?
    Below is a list of companies who compete with Akebia Therapeutics or are related in some way:
    • Bioventus Inc (BVS)
    • Corcept Therapeutics Inc (CORT)
    • Eli Lilly and Co (LLY)
    • NovaBay Pharmaceuticals Inc (NBY)
    • Palatin Technologies Inc (PTN)

Akebia Therapeutics Dividend Yield

Akebia Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 20%
Revenue: -22.58% -0.01%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 5.50
Upside from Last Price: 195.7%

Major Shareholders

  • How many AKBA shares are owned by institutional investors?
    92.4M AKBA shares are owned by institutional investors
  • How many AKBA shares are owned by insiders?
    7.9M AKBA shares are owned by insiders